At week 256 , and with > 4.5 years of golimumab , overall intent-to-treat Assessment in SpondyloArthritis international Society criteria for 20 % improvement ( ASAS20 ) and ASAS40 response rates were 66.0 % ( 235/356 ) and 57.0 % ( 203/356 ) , respectively ; Bath AS Disease Activity Index 50 % improvement response was 55.9 % ( 199/356 ) .